- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Overview/Mission
t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases.
t2cure is a biopharmaceutical company founded by Prof. Andreas M. Zeiher and Prof. Stefanie Dimmeler, both internationally renowned academic researchers at Frankfurt University. The founders of t2cure developed a therapeutic approach to effectively induce neo-vascularization and repair processes in ischemic tissue. The new therapeutics consist of autologousGlossary
t2cure is active in two therapeutic areas: cardiac diseases, with focus on myocardial infarction and chronic heart disease; and peripheral arterial diseases, with focus on thromboangiitis obliterans. More than 800 patients were treated with the progenitor cell-based therapy to date. The therapy is available to patients in Germany at specialized clinical centers.